A longer acting rFVIII, safe and effective
- PMID: 24434992
- DOI: 10.1182/blood-2013-12-539825
A longer acting rFVIII, safe and effective
Abstract
In this issue of Blood, Mahlangu et al describe a well-designed and executed phase 3 multicenter study of a recombinant factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hemophilia A.
Comment on
-
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.Blood. 2014 Jan 16;123(3):317-25. doi: 10.1182/blood-2013-10-529974. Epub 2013 Nov 13. Blood. 2014. PMID: 24227821 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

